ixekizumab (taltz) Report issue

Biologics mAb Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH repoDB

Active Ingredient History

NOW
  • Now
Ixekizumab, sold under the brand name Taltz, is an injectable medication for the treatment of autoimmune diseases. Chemically, it is a form of a humanized monoclonal antibody. The substance acts by binding interleukin 17A and neutralizing it, reducing inflammation.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$1284.7264

United States

$3909.8750 - $5241.5650
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

ixekizumab | ixekizumab (genetical recombination) | ly2439821 | ly-2439821 | taltz

Organizations (30)

Research & Development (30)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (21)

Approved Indications (1)


 

Psoriasis

Experimental Indications - Clinical Trial Phases 1-4 (21)


 

Arthritis (Phase 3)

Arthritis, Juvenile (Phase 3)

Arthritis, Psoriatic (Phase 4)

Arthritis, Rheumatoid (Phase 2)

Axial Spondyloarthritis (Phase 3)

Constriction, Pathologic (Phase 2)

COVID-19 (Phase 3)

Depressive Disorder, Major (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Healthy Volunteers (Phase 1)

Lichen Planus (Early Phase 1)

Panuveitis (Phase 4)

Pemphigoid, Bullous (Phase 2)

Pityriasis Rubra Pilaris (Phase 2)

Psoriasis ()

Pyoderma Gangrenosum (Phase 2)

Spondylitis, Ankylosing (Phase 3)

Substance Withdrawal Syndrome (Phase 3)

Uveitis, Anterior (Phase 4)

Uveitis, Intermediate (Phase 4)

Uveitis, Posterior (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 50
  • # of Trial Organizations: 30

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue